Navigation Links
Top-Line Efficacy Data Presented from Phase 2 Trial of Alemtuzumab in Multiple Sclerosis
Date:10/15/2007

Three-Year Analysis Demonstrates Robust, Highly Statistically Significant

Treatment Effect of Alemtuzumab Compared to Rebif(R)

CAMBRIDGE, Mass., Oct. 15 /PRNewswire-FirstCall/ -- Genzyme Corporation (Nasdaq: GENZ) today announced that top-line, three-year data from a completed Phase 2 clinical trial comparing alemtuzumab with Rebif(R) (interferon beta- 1a) for the treatment of multiple sclerosis were presented this weekend at the 23rd Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) in Prague. The results come from an analysis conducted after 36 months of treatment for 334 patients in the three-year trial.

Results of the primary outcomes from this trial were presented by Alastair Compston, professor of neurology and the head of the Department of Clinical Neurosciences at the University of Cambridge, United Kingdom, during the prestigious Charcot Award lecture at ECTRIMS.

Efficacy Results

Overall efficacy results demonstrate that alemtuzumab provides a significant treatment effect that has been found to last three years among patients in the study. Analysis of the first co-primary endpoint showed that patients taking alemtuzumab experienced at least a 73 percent reduction in the risk for relapse after three years of follow up when compared to patients treated with interferon beta-1a. This difference was highly statistically significant in favor of the alemtuzumab patients with a p-value less than the pre-specified value (p=0.00396) assigned for the three-year analysis.

Analysis of the other co-primary endpoint showed that patients taking alemtuzumab experienced at least a 70 percent reduction in the risk for progression of clinically
'/>"/>

SOURCE Genzyme Corporation
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related medicine technology :

1. Opexa Therapeutics Reports Positive Top-line Data in Phase I/II Extension Trial with Tovaxin for Multiple Sclerosis
2. Medivation to Host Conference Call to Discuss Top-Line 12-Month Results From Dimebon Alzheimers Disease Study
3. Evotec AG (DE) - Evotec Reports Positive Proof-of-Concept Top-Line Results with ...
4. Evotec Reports Positive Proof-of-Concept Top-Line Results with Insomnia Drug Candidate EVT 201
5. Peregrine Pharmaceuticals Reports Positive Top-Line Results in Bavituximab Combination Therapy Trial in Advanced Cancer Patients
6. Catalyst Pharmaceutical Partners, Inc. Announces Top-Line Results of Its Bioequivalence Study of CPP-109 (Vigabatrin), the Companys Investigational Drug to Treat Cocaine and Methamphetamine Addiction
7. Cobalis Expects to Report Phase III Top-Line Results in May
8. XenoPort Reports Positive Top-Line Phase 3 Trial Results of XP13512 in Restless Legs Syndrome
9. Amarin Reports Top-Line Results of two Phase III Studies of Miraxion in Huntingtons Disease
10. UCB Announces Positive Top-Line Phase III Results for Keppra as Adjunctive Therapy for Partial Onset Seizures in Paediatric Patients from One Month to Less than Four Years of Age
11. Opexa Therapeutics Reports Positive Top-line Data in Phase I/II Dose Escalation Trial with Tovaxin for Multiple Sclerosis
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/24/2014)... Calif. , Dec. 23, 2014 In response ... Doctors, Association of Sierra Leone , Direct ... Leone for the treatment of local health workers ... While a new dedicated Ebola care center was constructed for ... the facility is not available for local Sierra Leonean health ...
(Date:12/22/2014)... , Dec. 22, 2014  CytoSorbents Corporation (OTCQB:CTSOD), ... CytoSorb® blood purification technology to help fight deadly ... 28 countries worldwide, today announced the appointment of ... FACS, as its Senior Vice President of Clinical ... Dr. Di Russo is an accomplished ...
(Date:12/22/2014)... DUBLIN , Dec. 22, 2014 Research and ... addition of the "US Self-monitoring Blood Glucose Market" ... http://photos.prnewswire.com/prnh/20130307/600769 This market insight focuses ... in the United States . Reimbursement ... studied. Thorough product analyses for more than 73 SMBG ...
Breaking Medicine Technology:First Ebola Treatment Unit for Local Health Workers Arrives in Sierra Leone 2CytoSorbents Appoints Dr. Gregory B. Di Russo as Senior Vice President of Clinical Development 2CytoSorbents Appoints Dr. Gregory B. Di Russo as Senior Vice President of Clinical Development 3CytoSorbents Appoints Dr. Gregory B. Di Russo as Senior Vice President of Clinical Development 4CytoSorbents Appoints Dr. Gregory B. Di Russo as Senior Vice President of Clinical Development 5US Self-monitoring Blood Glucose Market 2
... Presented at ASCO Show 26% Partial Response, 63% Clinical Benefit ... ... June 3 Kosan Biosciences,Incorporated (Nasdaq: KOSN ) today announced ... activity in a Phase 2,trial when administered in combination with trastuzumab ...
... Breast Cancer Patients, ROCKVILLE, Md., June 3 ... pharmaceutical company developing,therapeutics for the treatment of cancer ... data for the MKC-1 Phase 2 study in,patients ... by Bryan P.,Schneider, M.D., Assistant Professor, Department of ...
Cached Medicine Technology:Kosan's Lead Hsp90 Inhibitor, Tanespimycin, Shows High Level of Activity in Trastuzumab Resistant/Refractory HER2-Positive Breast Cancer in a Phase 2 Trial 2Kosan's Lead Hsp90 Inhibitor, Tanespimycin, Shows High Level of Activity in Trastuzumab Resistant/Refractory HER2-Positive Breast Cancer in a Phase 2 Trial 3Kosan's Lead Hsp90 Inhibitor, Tanespimycin, Shows High Level of Activity in Trastuzumab Resistant/Refractory HER2-Positive Breast Cancer in a Phase 2 Trial 4Kosan's Lead Hsp90 Inhibitor, Tanespimycin, Shows High Level of Activity in Trastuzumab Resistant/Refractory HER2-Positive Breast Cancer in a Phase 2 Trial 5Kosan's Lead Hsp90 Inhibitor, Tanespimycin, Shows High Level of Activity in Trastuzumab Resistant/Refractory HER2-Positive Breast Cancer in a Phase 2 Trial 6EntreMed Presents MKC-1 Phase 2 Data at American Society of Clinical Oncology Annual Meeting 2EntreMed Presents MKC-1 Phase 2 Data at American Society of Clinical Oncology Annual Meeting 3EntreMed Presents MKC-1 Phase 2 Data at American Society of Clinical Oncology Annual Meeting 4
(Date:12/25/2014)... Recently, iFitDress.com, the popular online supplier of wedding dresses and ... of black one-shoulder cocktail dresses . In addition, all ... at discounted prices, up to 70% off. , ... weeks only. You know, we have thousands of frequent callers ... new items can visit our website for more details. The ...
(Date:12/25/2014)... 25, 2014 BambooFlooringChina.com sells many bamboo ... bamboo flooring. Today, the company announces big discounts ... styles and colors. , BambooFlooringChina.com is the world’s leader ... promotion is valid until Jan. 20, 2015. , The ... woven with a natural thread. All the bamboo strips ...
(Date:12/25/2014)... By Dennis Thompson ... -- Very sick children with complex chronic illnesses can receive ... a "medical home," with easy access to a team of ... were less likely to become seriously ill and need either ... received treatment at an enhanced medical home clinic at the ...
(Date:12/25/2014)... Dennis Thompson HealthDay Reporter ... closing in on a "fountain of youth" drug that can ... older adults, a new study suggests. Seniors received a ... that targets a genetic signaling pathway linked to aging and ... The experimental medication, a version of the drug ...
(Date:12/25/2014)... Plugin creators from Pixel Film Studios have ... business presentation tool made specifically for Final Cut ... tool, users can now display their stats and facts ... Studios. “ProFire 5k gives users a multiple options to ... a presentation” , Pixel Film Studios takes the heat ...
Breaking Medicine News(10 mins):Health News:iFitDress.com: Black One-Shoulder Cocktail Dresses for 2015 2Health News:Various Styles of Bamboo Mats in Many Colors from BambooFlooringChina.com 2Health News:Coordinated Care Through 'Medical Home' Best for Chronically Ill Kids: Study 2Health News:Coordinated Care Through 'Medical Home' Best for Chronically Ill Kids: Study 3Health News:Researchers Take 'First Baby Step' Toward Anti-Aging Drug 2Health News:Researchers Take 'First Baby Step' Toward Anti-Aging Drug 3Health News:Announcing a new ProFire 5k plugin from Pixel Film Studios for Final Cut Pro X Professionals 2
... YORK, Feb 26 Our faces are our calling ... and are connected with three out of the five ... what happens when what you see in the mirror ... News Release, go to: http://www.prnewswire.com/mnr/aafprs/35820/ If you have ...
... 26 Solos Endoscopy, Inc. (Pink Sheets: SNDY) is ... significant purchase order for the MammoView(TM) line of surgical ... Waterbury Hospital, the cornerstone of the Greater Waterbury Health ... care services since 1983 and is accredited by the ...
... Pharma, Inc.,(Nasdaq: IDMI ) today announced that ... and more than 100 patient organizations, caregivers,researchers and companies ... on February 28. The goal of the day ... by those affected and the importance,of research to develop ...
... (Nasdaq: STRM ) announced today that Jay ... of Directors. The addition of Mr. Miller brings to ... Health Board of Directors.Mr. Miller has spent roughly 25 ... development; sales and marketing; and profit and loss responsibilities. ...
... - Quarter Highlighted by Regulatory Approval of Once-Daily Tramadol in, ... for Novel Treatment for Depression -,LAVAL, QC, Feb. 26 /PRNewswire-FirstCall/ ... today reported its results for the fourth quarter and year ... unless otherwise stated. , "With our first product about to ...
... To Autism" and Provides Important Information on Early ... Toys"R"Us and Babies"R"Us stores nationwide will kick off ... Speaks, the nation,s leading organization dedicated to increasing ... the causes, prevention and treatments for autism; and ...
Cached Medicine News:Health News:Video: Facing the Facts - What You Need to Know About Facial Plastic Surgery 2Health News:Solos Endoscopy, Inc. Receives Purchase Order from Major Connecticut Hospital for the MammoView(TM) 2Health News:IDM Pharma Joins NORD to Raise Awareness of Rare Diseases 2Health News:IDM Pharma Joins NORD to Raise Awareness of Rare Diseases 3Health News:IDM Pharma Joins NORD to Raise Awareness of Rare Diseases 4Health News:Streamline Health Appoints Jay D. Miller to Board of Directors 2Health News:Streamline Health Appoints Jay D. Miller to Board of Directors 3Health News:Streamline Health Appoints Jay D. Miller to Board of Directors 4Health News:Labopharm Reports Results for Year End and Fourth Quarter Fiscal 2008 2Health News:Labopharm Reports Results for Year End and Fourth Quarter Fiscal 2008 3Health News:Labopharm Reports Results for Year End and Fourth Quarter Fiscal 2008 4Health News:Labopharm Reports Results for Year End and Fourth Quarter Fiscal 2008 5Health News:Labopharm Reports Results for Year End and Fourth Quarter Fiscal 2008 6Health News:Labopharm Reports Results for Year End and Fourth Quarter Fiscal 2008 7Health News:Labopharm Reports Results for Year End and Fourth Quarter Fiscal 2008 8Health News:Labopharm Reports Results for Year End and Fourth Quarter Fiscal 2008 9Health News:Labopharm Reports Results for Year End and Fourth Quarter Fiscal 2008 10Health News:Labopharm Reports Results for Year End and Fourth Quarter Fiscal 2008 11Health News:Labopharm Reports Results for Year End and Fourth Quarter Fiscal 2008 12Health News:Labopharm Reports Results for Year End and Fourth Quarter Fiscal 2008 13Health News:Labopharm Reports Results for Year End and Fourth Quarter Fiscal 2008 14Health News:Toys'R'Us and Babies'R'Us Launch In-Store Fundraising Campaign to Benefit Autism Speaks 2Health News:Toys'R'Us and Babies'R'Us Launch In-Store Fundraising Campaign to Benefit Autism Speaks 3
... of three software components that comprise ... ,Three software components comprise the SmartPill ... software, SmartPill Data Receiver software and ... are integrated and indispensable parts of ...
... software links sampler, patient and ... making data readily available to ... of incorrect patient identification. ... 1st automatic, the worlds first ...
... One of three software components ... System., ,Three software components comprise ... pH.p Capsule software, SmartPill Data Receiver ... three components are integrated and indispensable ...
... The standard pH Testing Application ... with the Bravo™ Catheter-Free pH ... Recorder, and the Synectics Digitrapper ... The PNET software and Digitrappers ...
Medicine Products: